241 related articles for article (PubMed ID: 20807412)
1. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
Lv G; Ying L; Ma WJ; Jin X; Zheng L; Li L; Yang Y
Virol J; 2010 Aug; 7():207. PubMed ID: 20807412
[TBL] [Abstract][Full Text] [Related]
2. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
3. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
4. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.
Liu YZ; Hou FQ; Ding P; Ren YY; Li SH; Wang GQ
Virol J; 2012 Nov; 9():274. PubMed ID: 23158844
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
[TBL] [Abstract][Full Text] [Related]
7. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
[TBL] [Abstract][Full Text] [Related]
9. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients.
Shi TD; Zhang JM; Wang XF; Chen M; Sun H; Chen CB; Ren H
Clin Exp Med; 2012 Jun; 12(2):105-13. PubMed ID: 21748522
[TBL] [Abstract][Full Text] [Related]
10. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
11. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
12. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
13. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
Lai Q; Ma S; Ge J; Huang Z; Huang X; Jiang X; Li Y; Zhang M; Zhang X; Sun J; Abbott WG; Hou J
PLoS One; 2014; 9(2):e88475. PubMed ID: 24551107
[TBL] [Abstract][Full Text] [Related]
14. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Pan CQ; Han GR; Jiang HX; Zhao W; Cao MK; Wang CM; Yue X; Wang GJ
Clin Gastroenterol Hepatol; 2012 May; 10(5):520-6. PubMed ID: 22343511
[TBL] [Abstract][Full Text] [Related]
15. Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection.
Ma XJ; Chen XF; Chen WL; Chen R; Huang J; Luo XD; Liao JY; Chen XP
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4675-4679. PubMed ID: 29131246
[TBL] [Abstract][Full Text] [Related]
16. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
Suh DJ; Um SH; Herrmann E; Kim JH; Lee YS; Lee HJ; Lee MS; Lee YJ; Bao W; Lopez P; Lee HC; Avila C; Zeuzem S
Antimicrob Agents Chemother; 2010 Mar; 54(3):1242-7. PubMed ID: 20028815
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
18. [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
Pan XC; Yang F; Chen M
Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):885-8. PubMed ID: 19105929
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
[TBL] [Abstract][Full Text] [Related]
20. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
